MULTICENTER AIDS COHORT STUDY

多中心艾滋病队列研究

• 批准号: 7066588
• 负责人: John P Phair
• 金额: $ 279.94万
• 依托单位: HOWARD BROWN HEALTH CENTER
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7066588
• 关键词: AIDS dementia complex; AIDS therapy; African American; HIV infections; Hispanic Americans; age difference; clinical research; combination chemotherapy; comorbidity; cooperative study; disease /disorder proneness /risk; epidemiology; homosexuals; host organism interaction; human immunodeficiency virus 1; human subject; human therapy evaluation; longitudinal human study; male; medical complication; opportunistic infections; outcomes research; pathologic process; prognosis; racial /ethnic difference; serology /serodiagnosis; sex behavior; socioeconomics; therapy adverse effect; therapy compliance; tissue resource /registry

DESCRIPTION (provided by applicant): The Chicago Multicenter AIDS Cohort Study (MACS) has made important contributions to the understanding of the natural history of treated and untreated HIV-1 infection. Continuation of the study into the era of widespread use of highly active antiretroviral therapy (HAART) allowed for the evaluation of the benefits of potent therapy, however, prolonged HIV-1 infection and/or the adverse effects of treatment could impact these benefits. The expanded cohort including 275 younger, predominantly African-American and Hispanic men, more accurately reflects the demographics of the epidemic in 2003 and allows for comparisons across racial, ethnic and age groups. The specific aims of the MACS for the next 5 years are to: i) assess the population effectiveness of long term HAART use and whether it is influenced by race/ethnicity; ii) delineate the heterogeneity and determinants of individual responses to HAART, with particular emphasis on the durability of the response in differing racial/ethnic and age groups; iii) determine the frequency of metabolic and cardiovascular adverse effects of HIV-1 and HAART; iv) characterize host genetic factors that distinguish long term non- and slow progressors from more rapid progressors prior to the use of HAART; v) further characterize the nature of resistance to infection in uninfected, highly exposed participants; vi) evaluate the impact of HAART, adherence, socioeconomic status, race/ethnicity and duration of HIV-infection on neurological outcomes and neuropsychological functioning; vii) examine the effect of co-infections, hepatitis B and C, and GB virus type C on the progression of HIV-1 infection and the response to HAART; viii) elucidate the pidemiology and pathogenesis of HIV-1 related malignant disease and the role of viral co-infections such as human herpesvirus type 8 and Epstein Barr virus; ix) continue to develop and implement innovative methods for the design and analysis of cohort studies of HIV/AIDS; x) continue to provide a platform for pathogenesis and other collaborative research. The Chicago investigators will contribute to each of these specific aims through maintenance of the cohort, core laboratories, capacity for data management and analysis, and active participation in the Executive Committee and Working Groups which develop the scientific agenda of the overall study,

描述（由申请人提供）： 芝加哥多中心艾滋病队列研究 (MACS) 为了解治疗和未治疗的 HIV-1 感染的自然史做出了重要贡献。 这项研究继续到广泛使用高效抗逆转录病毒疗法 (HAART) 的时代可以评估有效治疗的益处，然而，长期 HIV-1 感染和/或治疗的副作用可能会影响这些益处。 扩大后的队列包括 275 名年轻人，主要是非裔美国人和西班牙裔男性，更准确地反映了 2003 年流行病的人口统计数据，并可以进行跨种族、民族和年龄组的比较。 MACS 未来 5 年的具体目标是： i) 评估长期使用 HAART 的人群有效性以及是否受到种族/民族的影响； ii) 描述HAART个体反应的异质性和决定因素，特别强调不同种族/族裔和年龄组反应的持久性； iii) 确定 HIV-1 和 HAART 的代谢和心血管不良反应的频率； iv) 在使用HAART之前，表征区分长期非进展者和缓慢进展者与较快速进展者的宿主遗传因素； v) 进一步表征未感染、高度暴露的参与者对感染的抵抗力的性质； vi) 评估HAART、依从性、社会经济地位、种族/族裔和HIV感染持续时间对神经结果和神经心理功能的影响； vii) 检查合并感染、乙型和丙型肝炎以及丙型 GB 病毒对 HIV-1 感染进展和 HAART 反应的影响； viii) 阐明HIV-1相关恶性疾病的流行病学和发病机制以及病毒联合感染（例如人类疱疹病毒8型和Epstein Barr病毒）的作用； ix) 继续开发和实施创新方法来设计和分析艾滋病毒/艾滋病队列研究； x) 继续为发病机制和其他合作研究提供平台。芝加哥研究人员将通过维护队列、核心实验室、数据管理和分析能力以及积极参与制定整个研究的科学议程的执行委员会和工作组，为每一个具体目标做出贡献，